Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders

Silvio Bellino *,†, Paola Bozzatello †, Cristina Badino, Emanuela Mantelli and Paola Rocca

Center for Personality Disorders, Psychiatric Clinic, Department of Neuroscience, University of Turin, Via Cherasco 11, 10126 Turin, Italy; paola.bozzatello@unito.it (P.B.); cristina.badino@unito.it (C.B.); emanuela.mantelli@unito.it (E.M.); paola.rocca@unito.it (P.R.)
* Correspondence: silvio.bellino@unito.it; Tel.: +39-011-663-4848; Fax: +39-011-673473
† Silvio Bellino and Paola Bozzatello equally contributed to the review and can both be considered as first authors.

Abstract: It is the focus of increasing interest to investigate the effects of long-chain n-3 and long-chain n-6 polyunsaturated fatty acids (LC n-3 PUFAs; LC n-6 PUFAs) on psychiatric symptoms in a transdiagnostic perspective. There is some evidence that low levels of LC n-3 PUFAs and a higher ratio of LC n-6 to LC n-3 PUFAs in plasma and blood cells are associated with aggressive and impulsive behaviours. Therefore, implementation of LC n-3 PUFAs may produce positive effects on hostility, aggression, and impulsivity in both psychiatric and non-psychiatric samples across different stages of life. A possible mechanism of action of LC n-3 PUFAs in conditions characterized by a high level of impulsivity and aggression is due to the effect of these compounds on the serotonin system and membrane stability. Studies that evaluated the effects of LC n-3 PUFAs on impulsivity and aggressiveness indicated that addition of rather low doses of these agents to antipsychotic treatment might reduce agitation and violent behaviours in psychosis, attention deficit hyperactivity disorder, personality disorders, and impulsive control and conduct disorders. The present review is aimed at examining and discussing available data from recent trials on this topic.

Keywords: long-chain n-3 polyunsaturated fatty acids; long-chain n-6 polyunsaturated fatty acids; PUFAs; impulsive behaviours; aggressiveness; psychiatric disorders

1. Introduction

In the last two decades, there has been an increasing interest among investigators in the role of PUFAs in human health [1]. These agents cannot be synthesized by the human body but are obtained from diet and metabolic conversion [2]. The main long-chain n-3 PUFAs (LC n-3 PUFAs) include alpha linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), while the long-chain n-6 PUFAs (LC n-6 PUFAs) primarily involve gamma-linolenic acid (GLA) and arachidonic acid (AA).

Among LC n-3 PUFAs properties, they produce a protective effect on the inflammatory and cardiovascular systems, improving the lipid and lipoprotein profile and the endothelial function [3], and influence the downregulation of leukocyte cells and the concentrations of proinflammatory biomarkers related to atherosclerosis, such as chemokines and cytokines [4].

The role of LC n-3 PUFAs, essential compounds of the neuronal cell membranes, is now recognized in several brain functions. Some studies report that poor intake of EPA and DHA during the neurodevelopmental process produces consequences in terms of reduction of serotonin synthesis, storage, and release; impaired receptor function [5]; and deficit in neurogenesis, dendritic arborization, synaptogenesis, selective pruning, and myelination [6]. On the other hand, their supplementation can contribute to the prevention of the onset of cognitive disorders by the reduction of the neurotoxicity typical
of neurodegenerative disorders [7,8]. Moreover, there is some evidence that higher levels of LC n-3 PUFAs are associated with the improvement of stress coping in animal models [9].

Nutritional intervention trials on omega-3 fatty acids have been performed to test the effects of the intake of two important LC n-3 PUFAs, EPA and DHA. As these agents are not produced de novo by the body, but are obtained from their conversion from ALA or through dietary intake, experimental approaches are based on dietary supplementation. There is a growing interest in the nascent field of “nutritional psychiatry” and the potential for nutritional interventions to help improve mental health problems [10]. In particular, the discovery of low levels of EPA and DHA in the central nervous system of subjects with impulsive, aggressive, self-harm, and parasuicidal behaviours has encouraged investigators to conduct trials on LC n-3 fatty acids’ implementation [1,11–16]. These studies have been partly stimulated by findings from longitudinal studies showing that poor nutrition in infancy is associated with aggressive and antisocial behaviours [17], and even maternal diet poor of LC n-3 PUFAs during pregnancy is a predisposing factor of antisocial personality disorder in offspring [18].

The association between deficit of LC n-3 PUFAs and aggressive and impulsive behaviours has been observed in children and adolescents with conduct disorders and attention deficit hyperactivity disorder (ADHD) and in adults with schizophrenia, bipolar disorder, and personality disorders. Not only a lower plasma level of LC n-3 PUFAs but also an unbalanced LC n-6/LC n-3 PUFAs ratio was observed in psychiatric patients who expressed impulsive dyscontrol as the main symptom cluster, such as impulsive gamblers [19] and cocaine abusers [20].

The relationship between decreased LC n-3 PUFA availability and psychiatric conditions with high levels of impulsivity could be partly explained by the effect of these compounds on the serotonin system that is implicated in inhibiting impulsive aggression [21]. Depleting brain serotonin levels in normal individuals results in increased antisocial behaviours, uncontrolled aggression, and outbursts of anger [22]. On the opposite side, the stimulation of EPA on serotonin release and of DHA on membrane-embedded serotonin receptor accessibility produces a positive effect on cognitive functioning, propensity for prosocial behaviours, and control of impulsive reactions [23–25].

It is the focus of increasing interest to investigate the effects of polyunsaturated fatty acids (PUFAs) on dimensions of impulsivity and aggression in a transdiagnostic perspective [26,27]. The present review is aimed at examining available evidence on the effects of LC n-3 and n-6 PUFAs on these psychopathological dimensions throughout patients with psychotic disorders, personality disorders, attention-deficit hyperactivity disorder, and impulse control and conduct disorders.

2. Efficacy of PUFAs on Impulsive Behaviours and Aggressiveness in Schizophrenia

Schizophrenia is a mental disorder characterized by delusions, hallucinations, disorganized symptoms, apathy, abulia, anhedonia, social withdrawal, and cognitive deficits. Aggression and agitation in patients with schizophrenia and related psychoses are acute symptoms that constitute one of the main causes for admission to psychiatric hospitals [28].

Violent behaviours in schizophrenia can be determined by several conditions, such as the presence of positive psychotic symptoms, comorbidity with personality disorders, and a high level of impulsivity. Other factors that can contribute to aggressive conducts are neurological abnormalities, concomitant substance use, and poor medication adherence [29]. In recent years, some studies have investigated in patients with different stages of psychosis the potential correlation between impulsive-aggressive behaviours and low plasma levels of LC n-3 PUFAs [30,31]. For example, a study performed in patients with acute drug-free schizophrenia suggested that the concentration of fatty acids in red blood cells was inversely related with the hostility score in the Positive and Negative Syndrome Scale (PANSS) [32].

Current treatment of impulsive and aggressive behaviours in schizophrenia mainly relies on antipsychotics. In particular, the role of clozapine in reducing hostility and
aggression in patients with psychosis is generally recognized [33,34]. On the basis of the relationship between low LC n-3 PUFA plasma levels and impulsivity and aggressiveness in schizophrenia, some trials were performed with the intent to evaluate the benefits of supplementation of EPA and DHA in the treatment of this disorder, in monotherapy or more frequently in association with antipsychotic drugs.

The majority of clinical trials performed in schizophrenia were aimed at testing the efficacy of these agents in reducing the rate of progression to psychosis in high-risk subjects [35,36] or in improving positive and negative symptoms of patients with stable schizophrenia [37–39].

A limited number of studies have specifically evaluated the effects of EPA and DHA in the domains of impulsivity and aggressiveness in patients with schizophrenia.

Three clinical trials and one pilot study analysed the improvement of impulsiveness, aggressiveness, and hostility in patients with schizophrenia treated with LC n-3 PUFAs. One trial was conducted in adolescents at high risk of developing psychosis [35], while three studies were performed in patients with stable schizophrenia [40–42]. Trial duration ranged between 8 and 12 weeks; treatment doses of EPA and DHA ranged, respectively, between 0.54 and 1.2 g/day and between 0.36 and 0.6 g/day. In two studies [41,42], LC n-3 PUFAs were administered in addition to antipsychotics. In one study [35], they were used in monotherapy or in addition to antidepressants or anxiolytics. A study by Légaré et al. [40] focused on the treatment of resistant patients without specifying the use of previous medications (only benzodiazepine was mentioned). The evaluation instruments used to measure poor impulse control and aggressiveness/hostility were the PANSS and the Modified Overt Aggression Scale (MOAS).

This pilot study published by Légaré et al. [40] was conducted on 12 violent male inpatients with chronic schizophrenia. Data suggested that nutritional supplement with EPA and DHA may facilitate the reduction of agitation and global psychopathology among these patients. These promising results were confirmed by Qiao et al. [41] in a larger sample of 50 patients (30 males and 20 females) with stable schizophrenia and aggressiveness (MOAS score higher than 4) who were randomly assigned to receive either fish oil (n = 28) or placebo (n = 22) in a double-blind trial. MOAS scores declined more in the LC n-3 PUFAs group than in the placebo group at the end of the study period. Therefore, the authors concluded that patients with schizophrenia and aggressive/violent behaviours treated with PUFAs showed a mitigation of their abnormal conducts. In this study was not found a relationship between baseline plasma level of EPA and DHA and level of aggression (MOAS scores) in the enrolled subjects.

In a study conducted by Amminger et al. [35], 15 adolescents (14 were female, 1 male) were evaluated. They received LC n-3 PUFAs (n = 8) or placebo (n = 7) in a random way. The participants who were treated with EPA and DHA supplementation experienced a greater improvement in impulsivity than those in the placebo group. In addition, suspiciousness, inner tension, emotional withdrawal, and anxiety showed a significant decrease during the consumption of LC n-3 PUFAs.

On the opposite side, a study conducted by Qiao et al. [42] reported negative results. In fact, patients treated with EPA and DHA did not show a significant improvement of hostility and aggression after treatment. This double-blind, placebo-controlled trial was conducted in 67 acute hospitalized patients with schizophrenia (35 males and 32 females) who showed violent and aggressive behaviours. They were randomly assigned to a group with supplementation of LC n-3 PUFAs (n = 32) or a placebo group (n = 35) in addition to antipsychotics. A possible explanation of the negative results could be that in this study, the patients received a rather low concentration of EPA and DHA. Moreover, the authors administered vitamin E as placebo treatment, while in other studies (e.g. Légaré et al. [40]), vitamin E was supplemented together with LC n-3 PUFAs.

Although there are some encouraging data about the relationship between PUFAs and impulsive and aggressive behaviours, findings remain inconclusive because of small sample sizes and scarcity of trials that specifically investigate these symptom domains.
Results of randomized controlled trials (RCTs) are displayed in detail in Table 1.

Table 1. Randomized controlled trials and open trials of omega-3 PUFAs focused on impulsivity and aggression in patients at ultra-high risk (UHR) of psychosis and schizophrenia.

| Study (Year) [Ref.] | Intervention Arm(s) | Comparison Arm(s) | Sample | Treatment Duration | Results |
|---------------------|---------------------|-------------------|--------|--------------------|---------|
| Légaré et al., 2007 [40] | EPA 0.4 g + DHA 0.2 g 3 times daily + 400 IU's vitamin E | no comparison arm | 12 violent male inpatients with chronic schizophrenia | 12 weeks | ↓ agitation ($p = 0.015$), ↓ psychopathology ($p < 0.01$) |
| | DHA 0.36 g/day + EPA 0.54 g/day + antipsychotics | placebo + antipsychotics | 50 patients with stable schizophrenia | 12 weeks | ↓ violence ($p = 0.04$), but no improvement in positive and negative symptoms ($p = 0.86$) |
| Amminger et al., 2013 [35] | EPA 0.7 g/day + DHA 0.48 g/day + vitamin E 0.0076 g | placebo | 15 young individuals at UHR of psychosis | 12 weeks | ↑ impulse control ($p = 0.03$), ↑ level of functioning ($p = 0.01$) |
| Qiao et al., 2020 [42] | DHA 0.36 g/day + EPA 0.54 g/day + antipsychotics | placebo + antipsychotics | 67 acute hospitalized patients with stable schizophrenia | 8 weeks | no improvement in hostility ($p = 0.884$) or psychopathology ($p = 0.165$) |

3. Efficacy of PUFAs on Impulsive Behaviours and Aggressiveness in Personality Disorders

Personality disorders are enduring maladaptive patterns of behaviours, cognition, and inner experience exhibited across many contexts and deviating from those accepted by the individual’s culture. These patterns develop early, are inflexible, and are associated with significant distress or disability. Among personality disorders, the effects of LC n-3 PUFAs supplementation have been investigated in borderline personality disorder (BPD), in which impulsivity, inappropriate and intense anger, and aggressiveness constitute the core characteristics of the disease. Patients with BPD act on the spur of the moment without consideration of the consequences, have difficulty establishing a plan, have a sense of urgency, present self-harm behaviours, and engage in potentially self-damaging activities. Moreover, these patients have a certain degree of persistent hostility, frequent outburst of anger, and irritability in response to minor slights and insults. Around 0.5% of BPD patients in the community manifest externalized aggression in the form of interpersonal violence [43]. BPD shares the traits of impulsivity, irritability, anger, and propensity to engage in physical violence with antisocial personality disorder (ASPD) [43].

With regard to neurobiological basis, impulsive aggression in BPD has been defined as an unbalance between the “top–down” control maintained by frontal cortices [44–47] and the “bottom–up drives” provided by limbic regions [48]. The hippocampus may play an important role in the regulation of aggressive behaviours [49], and an inverse correlation between hippocampal volume and aggressive traits has been found in BPD patients [50].

The effects of supplementation of LC n-3 PUFAs in BPD consist in the improvement of core symptoms of BPD, like depression [51–53], self-harm behaviours [52–55], and stress reactivity [52].

In particular, four RCTs [35,51,55,56] focused on the effects of EPA and DHA on the dimensions of impulsivity, aggression, and anger in BPD. Three trials reported positive results of LC n-3 PUFA supplementation in reducing aggressiveness [51,55,56], while two studies showed an improvement of impulsive behaviours [35,55]. On the other hand, one follow-up study [56] did not obtain any evidence of long-lasting effects of LC n-3 PUFAs on impulsive behavioural dyscontrol.
Three studies \cite{51,55,56} were performed on patients with borderline personality disorder, while one study \cite{35} involved individuals at ultra-high risk (UHR) of developing psychosis, including 15 patients who had a diagnosis of BPD.

One study tested the effect of EPA alone \cite{51}, while the remaining ones studied the effects of the combination of EPA and DHA. Amminger et al. \cite{35} administrated also vitamin E (0.76 g/die) together with EPA and DHA. Daily PUFA doses ranged from 0.7 to 1.2 g for EPA and from 0.4 to 0.6 g for DHA. RCTs’ duration ranged from 8 to 12 weeks \cite{35,51,55,56}. Only one 24-week follow-up study was published \cite{56}.

The evaluation instrument used to assess aggressiveness was the same across trials (Modified Overt Aggression Scale (MOAS)). Bellino et al. \cite{55} and Bozzatello et al. \cite{56} studied impulsivity with the Barratt Impulsiveness Scale and used also the items “outbursts of anger” and “impulsivity” of the Borderline Personality Disorder Severity Index (BPDSI) to investigate, respectively, aggressiveness and impulsivity. In a study conducted by Amminger et al. \cite{35}, impulsive behaviours were assessed with the item “poor impulse control” of the Positive and Negative Syndrome Scale (PANSS).

The first study, published by Zanarini and Frankenburg \cite{51}, studied levels of aggressiveness and depression in a group of 30 BPD women with a mean age of 26.3 years, who were treated for 8 weeks with ethyl-eicosapentaenoic acid (E-EPA) \((n = 20)\) or placebo \((n = 10)\), in the absence of other psychotropic medications. Results led to the conclusion that the E-EPA group experienced a significantly greater decrease in overall aggression compared with the placebo group.

Amminger et al. \cite{35} assessed a group of 15 adolescents with BPD who also met the criteria for UHR of psychosis. The sample was composed of 14 females and 1 male with a mean age of 16.2 years, randomized to receive either LC n-3 PUFAs with vitamin E \((n = 8\) treated with EPA + DHA) or placebo \((n = 7)\) for a period of 12 weeks. The study investigated several symptoms, such as suspiciousness or persecution, tension, emotional withdrawal, anxiety, and poor impulse control, together with levels of social, occupational, and psychological functioning. In particular, impulsivity showed a significantly greater improvement in the group treated with LC n-3 PUFAs.

Two studies \cite{55,56} compared for 12 weeks combined therapy with EPA plus DHA and valproic acid \((n = 23)\) with single therapy with valproic acid \((n = 20)\) in 43 patients with BPD aged between 18 and 50 years. The findings showed a more pronounced reduction in the severity of self-rated and clinician-rated impulsive behavioural dyscontrol, outbursts of anger, and self-mutilating conduct in the group of patients treated with the association of valproate and LC n-3 PUFAs. In a follow-up study \cite{56}, the positive effect on impulsivity was lost, while the beneficial effect was maintained on outbursts of anger, which is a symptom domain often linked to impulsive and aggressive dyscontrol.

Therefore, in borderline personality disorder, supplementation of LC n-3 PUFAs achieved positive effects on reducing impulsivity, self-injuries, and anger, which are core symptoms of this pervasive mental illness. The results in these dimensions are encouraging, but evidence is still limited. If initial positive results were confirmed, LC n-3 PUFAs (EPA and DHA) would be a valid option for patients with personality disorders, together with standard treatment, such as antipsychotics and mood stabilizers \cite{57,58}. Furthermore, findings suggest that n-3 PUFAs may also be an effective and well-tolerated treatment in adolescents with BPD who are at risk of developing psychosis.

Results of RCTs are displayed in detail in Table 2.
Table 2. Randomized controlled trials and open trials of omega-3 PUFAs focused on impulsivity and aggression in personality disorders.

| Study (Year) | Intervention Arm(s) | Comparison Arm(s) | Sample | Treatment Duration | Results |
|--------------|---------------------|-------------------|--------|--------------------|---------|
| Zanarini and Frankenburg, 2003 [51] | Ethyl-EPA 1 g/day (with no standard psychiatric therapies) | placebo | 30 females with BPD | 8 weeks | ↓ aggression ($p < 0.0001$) |
| Amminger et al., 2013 [35] | EPA 0.7 g/day + DHA 0.48 g/day + vitamin E 0.0076 g | placebo | 15 adolescents with BPD who also met criteria for UHR for psychosis | 12 weeks | ↓ impulsivity ($p = 0.03$) |
| Bellino et al., 2014 [55] | EPA 1.2 g/day + DHA 0.8 g/day + valproate 800–1300 mg/day | valproate 800–1300 mg/day | 43 BPD outpatients | 12 weeks | ↓ impulsivity, anger, and self-mutilating conducts in the omega-3 fatty acid group ($p \leq 0.05$) |
| Bozzatello et al., 2018 [56] | EPA 1.2 g/day + DHA 0.8 g/day + valproate 800–1300 mg/day | valproate 800–1300 mg/day | 43 BPD outpatients | 24 weeks follow-up | omega-3 fatty acid group showed long-lasting effects on anger control ($p = 0.01$) |

4. Efficacy of PUFAs on Impulsive Behaviours and Aggressiveness in Impulse Control and Conduct Disorders

Disruptive, impulse-control, and conduct disorders are externalizing psychopathological disorders characterized by problems in self-control of emotion and behaviours [59]. They include poor impulse control, emotional dysregulation, and superficial affection. They also encompass antisocial behaviours with violation of social norms and rights of others through delinquency, property damage, aggressiveness, and rebellion against authority figures. These abnormal conducts represent a public health problem as they have a precocious onset in childhood or adolescence and are associated with substance abuse and violent and criminal behaviours in early stages of life [60,61].

4.1. Impulsive and Aggressive Behaviours in Subjects with No Diagnosis of Psychiatric Disorders

Even in the absence of a full diagnosis of psychiatric disorder, individuals with antisocial traits or violent behaviours showed a reduction in aggressive and impulsive conducts with the supplementation of dietary nutrients, including LC n-3 PUFAs [60,62–64]. Poor nutritional status at the age of 3 years has been found to predispose to externalizing behavioural problems throughout childhood and adolescence [17]. In particular, low plasma levels of total LC n-3 PUFAs and a trend towards a higher ratio of LC n-6 to n-3 PUFAs were observed in conditions with a high level of impulsivity and anger. For example, a lower plasmatic level of DHA was observed in habitually violent and impulsive male offenders compared with nonviolent individuals [65,66].

There is evidence of the effectiveness of LC n-3 PUFAs in reducing aggressive conducts in the non-psychiatric young population. For example, in a 12-week double-blind RCT conducted in UK adolescents aged 13–16 years, subjects from troubled backgrounds presented very low blood levels of DHA + EPA, and supplementation with these agents was useful to reduce the level of disruptive conducts, especially in adolescents with a high initial level of violations [67]. Similar results were observed in a sample of 8- to 16-year-old children who received EPA and DHA supplementation in the form of fruit juice drink during a period of 3 months. In this population, a statistically significant reduction in externalizing and internalizing behavioural problems was observed, with improvement continuing 6 months after treatment cessation [68]. LC n-3 PUFAs showed long-lasting effects on anger control (p = 0.01).
4.2. **Impulsive and Aggressive Behaviours in Subjects with a Diagnosis of Psychiatric Disorders**

Concerning clinical samples, one observational study [70] and three RCTs [71–73] were performed in patients with high risk of externalizing conduct or patients specifically diagnosed with externalizing behavioural disorders.

In the observational study, 942 children with ages ranging between 6 and 12 years with behavioural problems were monitored for 3 months. Subjects who received a supplementation of EPA and DHA showed a significant improvement in externalizing conducts [70]. The three RCTs evaluated the effects of LC n-3 PUFAs on aggressive and antisocial behaviours. One was performed in children at high risk of externalizing conducts, the others in young individuals specifically diagnosed with externalizing behavioural disorders [71–73]. All the three studies obtained positive results about the efficacy of supplementation with LC n-3 PUFAs in reducing aggressive and antisocial behaviours. More in detail, the first trial was conducted on young adult prisoners showing antisocial behaviour [71], the second compared LC n-3 PUFAs with cognitive behaviour therapy [72], and the third was performed by the same authors to evaluate LC n-3 PUFAs versus social skill interventions [73]. All studies tested the effects of the combination of EPA and DHA with daily doses ranging from 0.08 to 0.6 g for EPA and from 0.04 to 0.4 g for DHA. RCTs’ duration ranged from 3 to 9 months [71–73]. The evaluation instruments used to assess aggressiveness and antisocial behaviour were the same in the two trials performed by the same research group [72,73] and were represented by the Reactive–Proactive Aggression Questionnaire (RPQ), the Child Behaviour Checklist (CBCL), the Youth Self-Report (YSR), the Antisocial Personality Screening Device (APSD), the Conduct and Oppositional Defiant Disorder Scales (CODDS), and the Aggression Questionnaire (AQ). On the other hand, Gesh et al. [71] used the Survey Anger Scales to assess outbursts of anger and aggression.

Gesh et al. [71] studied aggressive and antisocial behaviours in 172 young adult prisoners with externalizing disorder, comparing the rates of disciplinary offences before and after supplementation with EPA and DHA along a period from a minimum of 2 weeks to a maximum of 9 months. The average time spent on supplementation was the same for the two groups: 142 days for the placebo group \((n = 90)\) and 143 days for the active group \((n = 72)\). Compared with the baseline, the effect on prisoners treated with supplements of PUFAs for a minimum of 2 weeks was calculated to be a 35.1% reduction in violent offences.

Raine et al. [72] analysed a sample of 290 children at high risk of conduct disorders aged between 11 and 12 years, who were randomly assigned to a group receiving LC n-3 PUFAs (EPA + DHA) alone \((n = 72)\) or to a group receiving cognitive behavioural therapy (CBT) alone \((n = 73)\) or to a group receiving LC n-3 PUFAs plus CBT \((n = 73)\) or to a group receiving placebo \((n = 72)\). Children who received LC n-3 PUFA supplementation showed a significant reduction in externalizing behaviours compared with the control group after 3 months of treatment. Furthermore, in children who received a combination of LC n-3 PUFAs and CBT were observed lower levels of externalizing behaviour in comparison with both: those who received CBT alone and those who received placebo at 6 months of follow-up [72]. Similar encouraging findings were obtained from another study performed by the same research group [73] on a clinical sample of 282 children with externalizing behaviour aged between 7 and 16 years who were randomly treated for 6 months with LC n-3 PUFAs \((n = 67)\), social skills training \((n = 66)\), a combination of LC n-3 PUFAs and social skills \((n = 75)\), and placebo \((n = 74)\). The outcome measures were reactive aggression and antisocial behaviour. The results suggested that LC n-3 PUFA supplementation produced a significant long-lasting decline in child-reported reactive aggression at 12 months of follow-up.

Among other psychopathological conditions characterized by poor impulse control, special attention should be paid to gambling disorder (GD) and substance use disorders (SUDs).
GD is a “behavioural” addiction characterized by an uncontrollable urge to keep gambling despite negative consequences on the individual’s life. In these conditions, dopamine dysregulation in the orbitofrontal and anterior cingulate cortices may be partially responsible for the compulsive behaviour and impulsivity [74]. Moreover, gambling, as well as drugs or alcohol, stimulates the reward system of the brain, which is responsible for the addiction behaviours [75]. Both individuals with SUDs and subjects with gambling disorder show impairments in risky decision making and in reflection impulsivity in comparison with control subjects [76]. This process may be mediated by diminished top–down control of the prefrontal cortex over subcortical processes, promoting motivations to engage in addictive behaviour [77].

In patients with gambling disorder, and in particular in more impulsive ones, a higher percentage composition of EPA and a lower arachidonic acid (AA)/EPA ratio and AA/DHA ratio were found in membranes of red blood cells. On the other hand, EPA seems to have a beneficial role in modulating physical and psychological symptoms associated with craving in addiction conducts throughout the decrease of inflammatory cytokines’ toxicity [78].

To substantiate the hypothesis that a link exists between omega-3 fatty acid deficiency and aggression in addiction, some authors reported that in patients with cocaine abuse and aggressive behaviours, there were lower plasma levels of DHA and a significant increase in the ratio of LC n-6 to LC n-3 PUFAs [20,79]. On the opposite side, other investigators reported that low plasma levels of EPA, but not of DHA, were associated with a higher degree of aggression and impulsivity in patients with major depression and comorbid substance use disorder [80].

The efficacy of LC n-3 PUFAs on aggressive behaviours in substance use disorders was investigated in two studies conducted by Buydens-Branchey in 2008 [79,81]: an RCT and a follow-up study, which compared EPA and DHA with placebo. These trials tested the effects of a combination of EPA and DHA at high doses: 3 g of EPA and 3 g of DHA administrated for 3 months and during a follow-up period of further 3 months. The evaluation instrument used to assess aggressiveness was anger score obtained with the modified version of the Profile of Mood States (POMS). Twenty-four men with substance use disorder were randomized to receive LC n-3 PUFAs (n = 13) or placebo (n = 11). The findings suggested that treatment with LC n-3 PUFAs was superior to that with placebo in diminishing outbursts of anger. These changes were associated with an increase in plasma in both EPA and DHA, but higher EPA levels were more robustly correlated with a reduction in anxiety, while an increase in DHA was more significantly associated with a reduction in outbursts of anger/aggression [79]. These favourable results were confirmed during a period of 3 months following treatment discontinuation [81].

Recent research about supplementation of LC n-3 PUFAs in patients with impulsive and aggressive/antisocial behaviours suggests that the efficacy of a dietary intervention in both children and adults could be stronger for more impulsive forms of aggressive behaviour and in impulsive individuals with substance abuse disorder.

Results of RCTs are displayed in detail in Table 3.
Table 3. Randomized controlled trials and open trials of omega-3 PUFAs focused on impulsivity and aggression in impulse control and conduct disorders.

| Study (Year) [Ref.] | Interventional Arm(s) | Comparison Arm(s) | Sample | Treatment Duration | Results |
|---------------------|-----------------------|-------------------|--------|-------------------|---------|
| Gesh et al., 2002 [71] | EPA 0.08 g + DHA 0.044 g | placebo | 172 young adult prisoners with externalizing disorder | from a minimum of 2 weeks to a maximum of 36 weeks | ↓ violent offences ($p = 0.03$) |
| Raine et al., 2016 [72] | DHA 0.3 g + EPA 0.2 g | cognitive behavioural therapy (CBT) alone or PUFAs + CBT or placebo | 290 children at high risk of conduct disorders | 12 weeks + 24 weeks’ follow-up | The PUFAs-only group showed reduced externalizing behaviour compared with controls at 12 weeks ($p = 0.044$). The PUFAs + CBT group scored reduced externalizing behaviour compared with both the CBT-only ($p = 0.031$) and control groups ($p = 0.023$) at 24 weeks. |
| Raine et al., 2017 [73] | DHA 0.4112 g + EPA 0.604 g | social skills training or PUFAs + social skills training or placebo | 282 children with externalizing behaviour | 24 weeks + 24 weeks’ follow-up | Omega-3 fatty acid supplementation produced a long-lasting decline in child-reported reactive aggression ($p = 0.042$). |
| Buydens-Branchey et al., 2008 [79] | EPA + DHA at high dose (3 g/day) | placebo | 24 patients with substance abuse | 12 weeks | ↓ outbursts of anger ($p = 0.040$) |

5. Efficacy of PUFAs on Impulsive Behaviours and Aggression in Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit hyperactivity disorder (ADHD) is a prevalent psychiatric disorder in the paediatric population [82] with onset before 7 years of age. The behavioural symptoms include inattention, impulsivity, hyperactivity, and often aggression. Patients with impulsive and aggressive behaviours in ADHD show a cortico-limbic dysfunction that underlies impulsive aggression and an aberrant prefrontal activity that is linked to poor response inhibition [83,84].

The primary treatment of ADHD involves pharmacotherapy with stimulant medications, such as methylphenidate, in combination with behavioural therapy. Although methylphenidate improves some conditions of comorbidity, its effectiveness in eliminating symptoms of ADHD is only partial [85]. Moreover, in children who display milder or subclinical levels of symptoms, an alternative treatment can be preferable to amphetamine-type stimulants. In this context has arisen the interest of researchers in nutritional supplementations.

Association between hyperactivity, impulsivity, and LC n-3 PUFAs deficiency has been documented [86,87] and may be mediated by mechanisms that include insufficient dietary intake, lower rate of conversion of short-chain PUFAs to long-chain PUFAs, or rapid metabolism of long-chain PUFAs [88].

The neurobiological mechanism underlying the effect of LC n-3 PUFAs supplementation in ADHD is not completely clear: some studies argue that neural integrity and function in prenatal development also depend on the levels of LC n-3 PUFAs. In particular, low levels of DHA in cord blood are associated with inattention and hyperactivity at 10 years of age [89].

Several trials have assessed the efficacy of PUFAs on oppositional behaviours, conduct problems, and aggression, which are core symptom dimensions in children or adolescents with ADHD.
Seventeen RCTs tested the effects of supplementation with PUFAs on the dimension of impulsive aggression in patients with ADHD aged between 4 and 18 years. Some studies have evaluated the efficacy of LC n-3 PUFAs (EPA and DHA), others have investigated the effects of a combination of LC n-3 and n-6 (gamma linolenic acid (GLA) and AA) PUFAs, and only one study compared the efficacy of LC n-3 PUFAs with that of LC n-6 PUFAs. Nine studies did not find significant correlation between PUFA treatment and amelioration of impulsivity and behavioural problems, while eight trials reported that supplementation of these agents significantly improved these symptom dimensions of the disorder. In these studies, EPA was administrated at doses ranging between 0.3 and 1.2 g/day, DHA between 0.3 and 0.65 g/day, GLA between 0.06 and 0.18 g/day, and AA at a dose of 0.04 g/day. Trials lasted 8 weeks to 12 months.

In order to assess impulsive and aggressive behaviours in ADHD, investigators used heterogeneous evaluation instruments, such as the Child Behaviour Checklist (CBCL) [90,91], Conners’ Parent Rating Scale (CPRS) and Teacher Rating Scale (CTRS) [92,93], and the Disruptive Behavior Disorders (DBD) Rating Scale [94]. In one study [95], aggression was assessed with a series of questions (for example, “Does he/she easily become angry/hostile?” or “Does he/she push, pat, kick other people or pull other people’s hair?”), while impulsivity was measured with the impatience test.

5.1. Efficacy of LC n-3 PUFAs in ADHD

Voigt et al. [90] provided in 54 ADHD children (42 males and 12 females) DHA or placebo for 4 months. All the patients received dietary supplementation in association with a maintenance therapy with stimulant medications. At the end of the trial, no changes of impulsivity were registered in this sample. In a similar way, a study performed by Hirayama et al. [95] treating 40 ADHD children (32 males and 8 females) with LC n-3 PUFAs alone or placebo did not register any changes in aggressive behaviours. Widenhorn-Müller et al. [91] evaluated in 95 children the effects of LC n-3 PUFAs (n = 46) against placebo (n = 49) on cognitive function and behavioural control. Supplementation with EPA and DHA improved working memory function but had no effect on other cognitive measures and behavioural control. In a study published by Anand and Sachdeva [96], clinical results did not reach statistical significance, although the 25 patients treated with LC n-3 PUFAs showed a greater reduction in all behavioural dimensions of ADHD compared with the 25 patients treated with placebo.

Another RCT involving 40 boys with ADHD and 39 healthy controls compared the effect of the administration of LC n-3 PUFAs with that of placebo on behaviour and cognition [97]. Significant improvements in inattention scores were observed for both the ADHD and control groups, while no significant effects were observed on the CBCL (Child Behaviour Checklist) Rule Breaking and Aggressive Behavior subscales. In an RCT of 150 children performed by Manor et al. [93], the key finding was a significant score decrease in the Global-Restless/Impulsive subscale of Conners’ Parent and Teacher Rating Scales in the group treated with LC n-3 PUFAs. Furthermore, children that switched to LC n-3 PUFA treatment from placebo showed a significant reduction in both parent- and teacher-rated subscale scores.

In an RCT performed by Gustafsson et al. [92], the authors tested the effect of EPA alone versus that of placebo in 92 children with oppositional and impulsive behaviours that were characterized by a lower concentration of EPA and a higher concentration of LC n-6 PUFAs in serum and blood cells at baseline. Supplementation of EPA entailed a proportional reduction in n-6 PUFA concentrations in favour of n-3 PUFAs and was associated with clinical improvement after 15 weeks of treatment. In a more recent study of the efficacy of EPA versus that of placebo, Chang et al. [98] reported that the EPA group (n = 48) improved more than the placebo group (n = 44) in attention and vigilance but not in impulsive behavioural control.
5.2. Efficacy of LC n-3 and n-6 PUFAs in ADHD

LC n-3 PUFAs were compared with LC n-6 PUFAs in one trial conducted on 37 children with ADHD who were randomly assigned to two treatment arms. Behavioural abnormalities improved in both groups, so also the efficacy of n-6 PUFAs cannot be excluded on the basis of these data [99]. However, these findings are in contrast with those of other studies performed in ADHD [92] and other psychiatric disorders, which indicated the efficacy of LC n-3 but not of LC n-6 fatty acids. Considering these controversial and contrasting findings, some investigations were aimed at evaluating the effects of the combination of LC n-3 and n-6 PUFAs.

Seventy-five patients (64 boys and 11 girls) were included in a study that failed to demonstrate the benefits of PUFAs on impulsivity [100]. This double-blind randomized placebo-controlled trial suggested that for the whole group of children and adolescents, supplementation of EPA, DHA, GLA, and vitamin E for 3 months was not statistically superior to that of placebo in improving impulsive control. There was a subgroup (26% of all the subjects in the active group, 7% in the placebo group) who responded with a clinical improvement in ADHD core symptoms and also in impulsivity, but this finding did not reach the statistical significance. Among the most recent studies that did not support the efficacy of PUFAs in the treatment of ADHD, a randomized placebo-controlled clinical trial [101] including 76 male adolescents with ADHD failed to show positive effects of EPA plus DHA with a low dose of GLA on aggression and impulsivity, together with depression and anxiety. Assareh et al. [102] enrolled 40 Iranian children who received EPA, DHA, and a low dose of LC n-6 PUFAs in association with methylphenidate. At the end of the period of study, the scores of inattention, hyperactivity, and impulsivity were not significantly different between groups.

Among RCTs that suggested a beneficial effect of PUFA supplementation on conduct problems, Stevens et al. [94] enrolled 47 children (41 males and 6 females) who were randomized to receive either a mixed fish oil containing DHA, EPA, GLA, and AA or an olive oil. For the majority of the outcome measures, improvement was consistently better in the PUFA group than in the olive oil group, but the treatment difference was significant on only two measures: parent-rated conduct problems and teacher-rated attention symptoms. Moreover, in the PUFA supplementation group, a greater number of participants showed a decrease in oppositional and deviant behaviours. In a similar way, Richardson and Puri [103] enrolled 41 children with ADHD and specific learning difficulties who were randomly allocated to a group receiving EPA + DHA + GLA + AA supplementation or a placebo group. The authors obtained significantly lower scores for cognitive problems and general behavioural problems in the group treated with PUFAs. A positive response with a combination of LC n-3 and n-6 PUFAs on impulsivity was also observed in a study including 167 Australian children (128 boys, 39 girls) who were treated without stimulant medications for 30 weeks [104].

In a study conducted by Perera et al. [105], 94 children (69 males and 25 females) received for 6 months dietary supplementation of a combination of LC n-3 and n-6 PUFAs (n = 48) or placebo (n = 46), both in association with methylphenidate and standard behavioural interventions. Aggressiveness and impulsivity significantly decreased with an enhancement of children’s cooperation with teachers and parents in the treatment group.

Barragan et al. [106] enrolled 90 subjects who were randomized to a group receiving LC n-3 PUFAs plus LC n-6 PUFAs (n = 30) or a group receiving long-acting methylphenidate (n = 30) or a group receiving a combination of PUFAs and methylphenidate (n = 30) for 12 months. Although slightly less effective than methylphenidate, LC n-3/n-6 PUFAs were found to be effective and well-tolerated by children with ADHD. The combination of LC n-3/n-6 PUFAs with methylphenidate did not offer any significant benefit over methylphenidate alone, but permitted the use of lower doses of this stimulant. ADHD symptoms decreased in all the treatment arms, but the symptoms of hyperactivity–impulsivity showed a significantly better improvement in the group who received LC n-3/n-6 PUFAs associated with methylphenidate than in the group treated with LC n-3/n-6 PUFAs.
6 PUFAs alone. Reduction of symptoms was slower in the arms treated with n-3/n-6 PUFAs than in the methylphenidate arm. Scale scores were stabilized after 8 weeks of treatment, suggesting long-term stabilization with n-3/n-6 PUFAs either alone or in combination.

Discrepancies in the findings of trials may be due to differences in sample selection and data analysis. We can conclude that supplementation of PUFAs in children with ADHD did produce a reduction in symptom severity, but this change was not statistically significant in some RCTs. Future studies should assess the most appropriate doses of LC n-3 PUFAs and follow up patients for longer periods. They should also clarify whether LC n-6 PUFAs can be usefully combined with LC n-3 PUFA compounds to increase results in this clinical population. The possibility that a more optimal PUFA intake during early years may decrease the prevalence of ADHD in children and adolescents should also be examined.

Results of RCTs are displayed in detail in Table 4.

Table 4. Randomized controlled trials and open trials of omega-3 PUFAs focused on impulsivity and aggression in patients with attention deficit hyperactivity disorder (ADHD).

| Study (Year) [Ref.] | Interventional Arm(s) | Comparison Arm(s) | Sample | Treatment Duration | Results |
|---------------------|-----------------------|-------------------|--------|-------------------|---------|
| Voigt et al., 2001 [90] | DHA 0.345 g/day + stimulant medication | placebo + stimulant medication | 54 ADHD children 6–12 years old | 4 months | no ↓ of impulsivity (p = 0.071) or of any ADHD symptom |
| Hirayama et al., 2004 [95] | DHA 3.6 g/week (2 cases under medication) | placebo (4 cases under medication) | 40 ADHD children 6–12 years old | 4 months | no ↓ aggressive behaviours (p = 0.053) |
| Johnson et al., 2009 [100] | EPA 0.558 g/day + DHA 0.174 g/day + GLA 0.06 g/day | placebo | 75 ADHD children and adolescents 8–18 years old | 6 months | no ↓ impulsive control (p = 0.08) or of other ADHD symptoms |
| Widenhorn-Müller et al., 2014 [91] | EPA 0.6 g/day + DHA 0.120 g/day | placebo | 95 ADHD children 6–12 years old | 16 weeks | no effects on behavioural symptoms (CBCL Aggressive Behavior, p = 0.29; Delinquent Behavior, p = 0.58) or other cognitive measures (LNS, p = 0.092; Digits Forward task, p = 0.46), but ↑ of working memory function (p = 0.019) |
| Anand and Sachdeva 2016 [96] | EPA 0.18 g and DHA+ atomoxetine 0.12 g + atomoxetine 0.5 mg/kg/day | 50 ADHD children 4–11 years old | 4 months | ↓ hyperactive and impulsive symptoms, although the effect was not significant (p = 0.08) |
| Matsudaira et al., 2015 [101] | EPA 0.558 g and DHA 0.174 g, c-linoleic acid 0.06 g, and vitamin E 0.0096 g | placebo | 76 male adolescents 12–16 years old | 12 weeks | no improvement in aggression and impulsivity, depression and anxiety (p = 0.671) |
| Bos et al., 2015 [97] | EPA 0.65 g/day + DHA 0.65 g/day | placebo | 40 young boys 8–14 years old with and without ADHD | 16 weeks | ↑ attention scores (p < 0.001), no significant effects on aggression |
| Assareh et al., 2017 [102] | DHA 0.241 g, EPA 0.033 g, and omega-6 fatty acids + methylphenidate 0.180 g | placebo + methylphenidate | 40 ADHD patients 6–12 years old | 10 weeks | no improvement in impulsivity (p = 0.919), inattention (p = 0.691), and hyperactivity (p = 0.811) |
| Study (Year) | Interventional Arm(s) | Comparison Arm(s) | Sample | Treatment Duration | Results |
|-------------|-----------------------|------------------|--------|-------------------|---------|
| Chang et al., 2019 [98] | EPA 1.2 g/day | placebo (soybean oil 1.2 g) | 92 ADHD children and adolescents 6–18 years old | 12 weeks | ↑ attention (p = 0.041), ↑ focused attention (p = 0.015), and ↑ vigilance (p = 0.036), but no improvement in impulsive behavioural control |
| Richardson and Puri, 2002 [103] | EPA 0.186 g/day + DHA 0.480 g/day + linolenic acid 0.864 g/day + arachidonic acid 0.04 g/day | placebo | 41 children 8–12 years old with ADHD and specific learning difficulties | 12 weeks | ↓ cognitive problems (p = 0.01) and ↓ general behavioural problems (p = 0.02) |
| Stevens et al., 2003 [94] | DHA 0.48 g/day + EPA 0.08 g/day + arachidonic acid 0.04 g/day + GLA 0.096 g/day, vitamin E 0.024 g/day | placebo (olive oil 6.4 g/day) | 50 children 6–13 years old with ADHD-like symptoms | 4 months | ↓ conduct problems (p = 0.05), ↑ attention symptoms (p = 0.03), ↓ oppositional and deviant behaviours (p = 0.02) |
| Sinn and Bryan, 2007 [104] | EPA 0.558 g + DHA 0.174 g + GLA 0.060 g + vitamin E 0.018 g | placebo (palm oil) | 167 Australian children 7–12 years old | 30 weeks | ↓ impulsivity/hyperactivity (p < 0.01), inattention (p < 0.01) |
| Manor et al., 2012 [93] | PS 0.3 g and EPA 0.120 g + DHA (EPA/DHA ratio of 2:1) | placebo | 150 children | 15 weeks | ↓ impulsivity (p < 0.05) and other ADHD symptoms |
| Belanger et al., 2009 [99] | EPA 0.02–0.025 g/kg/day + DHA 0.85–0.105 g/kg/day | placebo (sunflower oil 500 mg) | 37 children 6–11 years old with ADHD | 16 weeks | ↓ behavioural problems and inattention (p < 0.05) |
| Gustafsson et al., 2010 [92] | EPA 0.5 g/day | placebo | 92 ADHD children 7–12 years old | 15 weeks | ↓ symptoms in two ADHD subgroups: oppositional (p = 0.01) and less hyperactive/impulsive children (p = 0.03) |
| Perera et al., 2012 [105] | omega-3 fatty acids 0.29637 g + omega-6 0.18075 g (ratio of 1.6:1) + methylphenidate and standard behavioural intervention | placebo with ADHD medications | 98 ADHD children 6–12 years old | 6 months | ↓ aggressiveness (p = 0.000), ↓ impulsiveness (p = 0.009) and ↑ cooperation with teachers and parents (p = 0.009), no improvement in distractibility |
| Barragan et al., 2017 [106] | omega-3/6, fatty acids, or combination of omega-3/6 fatty acids and methylphenidate | methylphenidate | 90 ADHD children 6–12 years old | 12 months | ↓ hyperactivity–impulsivity in the group treated with omega-3/6 + MPH vs. omega-3/6 alone (p = 0.009), no significant difference in hyperactivity–impulsivity between omega 3/6 treatment and MPH alone, and ↓ adverse events in the group with combined treatment vs. MPH alone (p = 0.001) |
6. Reviews and Meta-Analyses

Evidence suggests that LC n-3 PUFAs play a positive role in the treatment of several mental disorders and have been shown to improve both mood and behaviour. However, there is little consensus on whether LC n-3 PUFAs are beneficial for improving impulsivity and aggression. In the current literature, seven reviews and one meta-analysis have evaluated the efficacy of PUFAs in these psychopathological domains.

The examination of reviews and meta-analyses is of particular interest in order to explore whether we can draw final conclusions from the whole pool of data collected from single trials.

The meta-analysis performed by Gajos and Beaver in 2016 [15] involved 7173 participants with and without neurodevelopmental/behavioural disorders and supported the relationship between LC n-3 PUFA intake and reduced aggression in both child and adult populations, both within intervention trials and observational studies. Moreover, LC n-3 PUFAs were observed to have a stronger effect in reducing violent and aggressive behaviours, rather than misconduct behaviours, indicating their potential role in dealing with more serious aggressive actions towards others. On the other hand, LC n-3 PUFAs seemed to be less effective on disobedient behaviours typically observed in younger populations [15].

Regarding the reviews, five studies [13,27,60,107,108] found encouraging results about the efficacy of LC n-3 PUFAs on aggression and impulsivity. On the contrary, two other reviews [109,110] highlighted methodological shortcomings or inconclusive evidence. In a review performed by Hallahan and Garland [13], the authors analysed a number of psychopathological phenomena and psychiatric disorders characterized by impulsivity and identified a significant correlation between deficits of LC n-3 PUFAs and higher impulsivity levels. Furthermore, these clinical conditions were ameliorated by the supplementation of LC n-3 PUFAs, with an improvement of impulse dyscontrol. In a following review by the same authors [107], patients characterized by high levels of impulsivity, hostility, and aggression were considered. Data showed an association, at either the epidemiological or clinical level, between decreased levels of LC n-3 PUFAs and higher levels of anger, impulsivity, and hostility. The correction of this deficiency with supplementation of PUFAs may result in clinical improvement. Bozzatello et al. [108] explored the impact of fatty acids on impulsive and aggressive behaviours in a review that analysed the effects of supplementation of these compounds in psychiatric disorders. Although results are encouraging and there is some evidence supporting the use of LC n-3 PUFAs in the treatment of conditions characterized by high levels of impulsivity and aggression, the authors conclude that this area of psychopathology needs further investigations. In a review of intervention studies focusing on the relationship between LC n-3 PUFAs and aggressive behaviour, Choy and Raine [60] found a small effect size of PUFA supplementation in reducing aggressive and antisocial conducts in both children and adults. The authors proposed the hypothesis that the efficacy of LC n-3 PUFA intake might be stronger in more impulsive forms of aggressive behaviour. Bozzatello et al. [27] studied the efficacy of LC n-3 PUFAs in psychiatric disorders with a transdiagnostic perspective, analysing multiple dimensions, including impulsivity and aggressiveness. The authors presented evidence of the beneficial effects of EPA and DHA supplementation on reducing levels of impulsivity, outbursts of anger, and overt aggression.

Hamazaki and Hamazaki [109] performed a review in which the majority of studies showed the aggression/hostility-controlling effects of fatty acids. However, because of different assessment methods used in these studies, it appears to be difficult to come to a clear conclusion about the role of PUFAs as modulators of aggression and hostility.

In a review published by Appleton et al. [110], results on the effects of LC n-3 PUFAs on aggression and hostility were inconclusive. Although some clinical studies have found associations between LC n-3 PUFAs and these dimensions, others have failed in this purpose. The authors suggested that inconclusive results may be due to the fact that LC n-3 PUFA supplementation produces its effect mainly in stressful situations. In addition,
these compounds may reduce levels of aggression when they are expressed in vulnerable situations or in individuals with an innate tendency towards violent behaviour. Despite heterogeneous and inconsistent results, the authors highlighted the need for oncoming high-quality investigations about this issue.

Concerning tolerability, lack of severe adverse effects and general good tolerability are significant reasons to carefully consider the therapeutic potential of these agents. The most common side effects reported in clinical trials were nausea and a fishy aftertaste, but they were mild and rarely induced discontinuation [111]. Available data are insufficient to establish a tolerable daily intake of DHA and EPA in monotherapy or in combination, but supplementation of EPA and DHA up to 5 g/day is not dangerous for the general population [112]. In particular, EPA and DHA are generally recognized as safe and well tolerated at doses up to 5 g/day in terms of bleeding risk, as pointed out by Yokoyama et al. [113] and Tanaka et al. [114]. In addition, doses up to 5 g/day, consumed for a maximum period of 12–16 weeks, do not significantly affect glucose regulation in both healthy and diabetic subjects [115–118], do not increase infection risk by the activation of inappropriate inflammatory responses [119], and do not induce cardiovascular risk by the alteration of lipid metabolism [120]. In fact, combined intake of EPA and DHA at a dose of 2–6 g/day and intake of DHA at a dose of 2–4 g/die are responsible for an LDL concentration increase (3%) but do not affect cardiovascular risk. Intake of EPA at a maximum dose of 4 g/day does not induce significant changes in LDL plasma levels [121].

Author Contributions: S.B. and P.B. have organised and written the manuscript; C.B. and E.M. collected and checked the studies included in the review; P.R. have supervised and corrected the review. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the funds of the Italian Ministry of Health for the Departments of Excellence.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Acronym | Description                        |
|---------|------------------------------------|
| PUFAs   | Polyunsaturated fatty acids        |
| EPA     | Eicosapentaenoic acid              |
| DHA     | Docosahexaenoic acid               |
| ethyl-EPA| ethyl-eicosapentaenoic acid        |
| GLA     | Gamma-linolenic acid              |
| PS      | Phosphatidylserine                 |
| ↓       | Decrease of                        |
| ↑       | Increase of                        |
| IUs     | International Units               |
| >       | Superior of                        |
| <       | Inferior of                        |
| ADHD    | Attention Deficit Hyperactivity Disorder |
| BPD     | Borderline Personality Disorder    |
| LNS     | Letter-Number Sequencing           |

References

1. Shahidi, F.; Ambigaipalan, P. Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. *Annu. Rev. Food Sci. Technol.* 2018, 9, 345–381. [CrossRef] [PubMed]
2. Uauy, R.; Dangour, A.D. Fat and fatty acid requirements and recommendations for infants of 0–2 years and children of 2–18 years. *Ann. Nutr. Metabol.* 2009, 55, 6–96.
3. Ruiz-León, A.M.; Lapuente, M.; Estruch, R.; Casas, R. Clinical advances in immunonutrition and atherosclerosis: A review. *Front. Immunol.* 2019, 10, 837. [CrossRef] [PubMed]
4. Burke, A.C.; Huff, M.W. Regression of atherosclerosis: Lessons learned from genetically modified mouse models. *Curr Opin Lipidol.* 2018, 29, 87–94. [CrossRef]
5. Innis, S.M. Dietary (n-3) fatty acids and brain development. *J. Nutr.* 2007, 137, 855–859. [CrossRef]
6. Georgieff, M.K.; Innis, S.M. Controversial nutrients that potentially affect preterm neurodevelopment: Essential fatty acids and iron. *Pediatr. Res.* 2005, 57, 99R–103R. [CrossRef]

7. Lopez, L.B.; Kritz-Silverstein, D.; Barrett-Connor, E. High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: The Rancho Bernardo study. *J. Nutr. Health Aging.* 2011, 15, 25–31. [CrossRef]

8. Lefkowitz, D.L.; Lefkowitz, S.S. Microglia and myeloperoxidase: A deadly partnership in neurodegenerative disease. *Free Radic. Biol. Med.* 2008, 45, 726–731. [CrossRef]

9. Gonzales, E.; Barnett, D.W.; Shumake, J.; Gonzalez-Lima, F. Omega-3 fatty acids improve behavioral coping to stress in multiparous rats. *Behav. Brain Res.* 2015, 15, 129–138. [CrossRef]

10. Jacka, F.N. Nutritional Psychiatry: Where to Next? *EBioMedicine* 2017, 17, 24–29. [CrossRef]

11. Hamazaki, T.; Sawazaki, S.; Itomura, M.; Asaoka, E.; Nagao, Y.; Nishimura, N.; Yazawa, K.; Kuwamori, T.; Kobayashi, M. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. *J. Clin. Invest.* 1996, 97, 1129–1133. [CrossRef] [PubMed]

12. Iribarren, C.; Markovitz, J.H.; Jacobs, D.R., Jr.; Schreiner, P.J.; Daviglus, M.; Hibbeln, J.R. Dietary intake of n-3, n-6 fatty acids and fish: Relationship with hostility in young adults—the CARDIA study. *Eur. J. Clin. Nut.* 2004, 58, 24–31. [CrossRef] [PubMed]

13. Hallahan, B.; Garland, M.R. Essential fatty acids and their role in the treatment of impulsivity disorders. *Prostaglandins Leukot. Essent. Fatty Acids* 2004, 7, 211–216. [CrossRef] [PubMed]

14. Itomura, M.; Hamazaki, K.; Sawazaki, S.; Kobayashi, M.; Terasawa, K.; Watanabe, S.; Hamazaki, T. The effect of fish oil on physical aggression in schoolchildren—A randomized, double-blind, placebo-controlled trial. *J. Nutr. Biochem.* 2005, 16, 163–171. [CrossRef] [PubMed]

15. Gajos, J.M.; Beaver, K.M. The effect of omega-3 fatty acids on aggression: A meta-analysis. *Neurosci. Biobehav. Rev.* 2016, 69, 147–158. [CrossRef] [PubMed]

16. Meyer, B.J.; Byrne, M.K.; Collier, C.; Parletta, N.; Crawford, D.; Winberg, P.C.; Webster, D.; Chapman, K.; Thomas, G.; Dally, J.; et al. Baseline omega-3 index correlates with aggressive and attention deficit disorder behaviours in adult prisoners. *PLoS ONE* 2015, 10, e0120220.

17. Liu, J.; Raine, A.; Venables, P.H.; Mednick, S.A. Malnutrition at age 3 years and externalizing behavior problems at ages 8, 11, and 17 years. *Am. J. Psychiatt.* 2004, 161, 2005–2013. [CrossRef]

18. Neugebauer, R.; Hoek, H.W.; Susser, E. Prenatal exposure to wartime famine and development of antisocial personality disorder in early adulthood. *JAMA* 1999, 282, 455–462. [CrossRef]

19. Sanchez-Paez, P.; Perez-Templado, J.; Saiz-Ruiz, J.; Pastor, O.; Ibanez, A. Essential fatty acids and Barratt impulsivity in gambling disorder. *BMC Psychiatry* 2020, 20, 109. [CrossRef] [PubMed]

20. Buydens-Branchey, L.; Branchey, M.; McMakin, D.L.; Hibbeln, J.R. Polyunsaturated fatty acid status and aggression in cocaine addicts. *Drug Alcohol. Depend.* 2003, 71, 319–323. [CrossRef]

21. Seo, D.; Patrick, C.J.; Kennealy, P.J. Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders. *Aggress. Violent. Behav.* 2013, 18, 383–395. [CrossRef] [PubMed]

22. Passamonti, L.; Crockett, M.J.; Apergis-Schoute, A.M.; Clark, L.; Rowe, J.B.; Calder, A.J.; Robbins, T.W. Effects of acute tryptophan depletion on prefrontal-amygdala connectivity while viewing facial signals of aggression. *Biol. Psychiatry* 2012, 71, 36–43. [CrossRef] [PubMed]

23. Kidd, P.M. Omega-3 DHA and EPA for cognition, behavior, and mood: Clinical findings and structural-functional synergies with cell membrane phospholipids. *Altern. Med. Rev.* 2007, 12, 207–227. [PubMed]

24. Yang, Y.; Raine, A. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: A meta-analysis. *Psychiatt. Res.* 2009, 174, 81–88. [CrossRef] [PubMed]

25. Patrick, R.P.; Ames, B.N. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. *FASEB J.* 2015, 29, 2207–2222. [CrossRef]

26. Bozzatello, P.; Rocca, P.; Mantelli, E.; Bellino, S. Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders? *Int. J. Mol. Sci.* 2019, 20, 5257. [CrossRef]

27. Bozzatello, P.; De Rosa, M.L.; Rocca, P.; Bellino, S. Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology. *Int. J. Mol. Sci.* 2020, 21, 6042. [CrossRef]

28. Colasanti, A.; Natoli, A.; Molimento, D.; Rossattini, M.; De Gaspari, I.F.; Mauri, M.C. Psychiatric diagnosis and aggression before acute hospitalisation. *Eur. Psychiatry* 2008, 23, 441–448. [CrossRef]

29. Witt, K.; van Dorn, R.; Fazel, S. Risk factors for violence in psychosis: Systematic review and meta-regression analysis of 110 studies. *PloS ONE* 2013, 8, e55942. [CrossRef]

30. Reddy, R.D.; Keshavan, M.S.; Yao, J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. *Schizophr. Bull.* 2004, 30, 901–911. [CrossRef]

31. Van Der Kemp, W.J.; Klomp, D.W.; Kahn, R.S.; Luijten, P.R. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. *Schizophr. Res.* 2012, 141, 153–161. [CrossRef]

32. Watari, M.; Hamazaki, K.; Hirata, T.; Hamazaki, T.; Okubo, Y. Hostility of drug-free patients with schizophrenia and n–3 polyunsaturated fatty acid levels in red blood cells. *Psychiatry Res.* 2010, 177, 22–26. [CrossRef] [PubMed]

33. Volavka, J.; Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. *Int. J. Clin. Pract.* 2008, 62, 1237–1245. [CrossRef] [PubMed]
34. Krakowski, M.I.; Czobor, P.; Citrome, L.; Bark, N.; Cooper, T.B. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. *Arch. Gen. Psychiatry* 2006, 63, 622–629. [CrossRef] [PubMed]

35. Amminger, G.P.; Chanen, A.M.; Ohmann, S.; Klier, C.M.; Mossaheb, N.; Bechdolf, A.; Nelson, B.; Thompson, A.; McGorry, P.D.; Yung, A.R.; et al. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: A post hoc subgroup analysis of a double-blind, randomized controlled trial. *Can. J. Psychiatry* 2013, 58, 402–408. [CrossRef]

36. Amminger, G.P.; Schäfer, M.R.; Schlögelhofer, M.; Klier, C.; McGorry, P. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. *Nat. Commun.* 2015, 6, 7934. [CrossRef]

37. Jamilian, H.; Solhi, H.; Jamilian, M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. *Glob. J. Health Sci.* 2014, 18, 103–108. [CrossRef] [PubMed]

38. Emsley, R.; Myburgh, C.; Oosthuizen, P.; van Rensburg, S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. *Am. J. Psychiatry* 2002, 159, 1596–1598. [CrossRef]

39. Peet, M.; Horrobin, D.F.; Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. *J. Psychiatr. Res.* 2002, 36, 7–18. [CrossRef]

40. Légaré, N.; Brosseau, É.; Joyal, C.C. Omega-3 and violence in schizophrenia. *Schizophr. Res.* 2007, 96, 269. [CrossRef]

41. Qiao, Y.; Mei, Y.; Han, H.; Liu, F.; Yang, X.M.; Yang, S.; Xie, B.; Long, B. Effects of Omega-3 in the treatment of violent schizophrenia patients. *Schizophr. Res.* 2018, 195, 283–285. [PubMed]

42. Qiao, Y.; Liu, C.; Han, H.; Liu, F.; Shao, Y.; Xie, B. No Impact of Omega-3 Fatty Acid Supplementation on Symptoms or Hostility among Patients with Schizophrenia. *Front. Psychiatry* 2020, 11, 312. [CrossRef] [PubMed]

43. Sarkar, J. Borderline personality disorder and violence. *Australas. Psychiatry* 2019, 27, 578–580. [CrossRef] [PubMed]

44. Bellini, M.; Cerruti, S.; Brambilla, P. Orbitofrontal cortex abnormalities in schizophrenia. *Epidemiol. Psychiatr. Soc.* 2010, 19, 23–25. [CrossRef]

45. Chlorae, A.M.; Velakouilis, D.; Carson, K.; Gauison, K.; Wood, S.J.; Yuen, H.P.; Yucel, M.; Jackson, H.J.; McGorry, P.D.; Pantelis, C. Orbitofrontal, amygdala and hippocampal volumes in teenagers with first-presentation borderline personality disorder. *Psychiatry Res.* 2008, 163, 116–125. [CrossRef]

46. Matsuo, K.; Nicoletti, M.; Nemoto, K.; Hatch, J.P.; Peluso, M.A.; Nery, F.G.; Soares, J.C. Atypical antipsychotic agents in the treatment of violent patients. *Cognitive Transdiagnostic Variables: A Systematic Review.* 2010, 16, CD005653. [CrossRef] [PubMed]

47. Soloff, P.H.; Meltzer, C.C.; Becker, C.; Greer, P.J.; Kelly, T.M.; Constantine, D. Impulsivity and prefrontal hypometabolism in schizophrenia. *Arch. Gen. Psychiatry* 2006, 63, 622–629. [CrossRef] [PubMed]

48. Siever, L.J. Neurobiology of aggression and violence. *Am. J. Psychiatry* 2008, 165, 429–442. [CrossRef]

49. Malamud, N. Psychiatric disorder with intracranial tumors of limbic system. *Arch. Neurol.* 1967, 17, 113–123. [CrossRef]

50. Zetzsche, T.; Preuss, U.W.; Frodl, T.; Schmitt, G.; Seifert, D.; Munchhausen, E.; Tabrizi, S.; Leinsinger, G.; Born, C.; Reiser, M.; et al. Hippocampal volume reduction and history of aggressive behaviour in patients with borderline personality disorder. *Psychiatry Res.* 2007, 154, 157–170. [CrossRef]

51. Zanarini, M.C.; Frankenburg, F.R. Omega-3 fatty acid treatment of women with borderline personality disorder: A double blind, placebo-controlled pilot study. *Am. J. Psychiatry* 2003, 160, 167–169. [CrossRef] [PubMed]

52. Hallahan, B.; Hibble, J.R.; Davi, J.M.; Garland, M.R. Omega-3 fatty acids supplementation in patients with recurrent self-harm: Single center double blind randomized controlled trial. *Br. J. Psychiatry* 2007, 190, 118–122. [CrossRef] [PubMed]

53. Gallagher, A.T.; Byrne, F.; Murray, I.T.; Lally, J.; Davis, J.M. Lipids and polyunsaturated fatty acid levels in deliberate self-harm: A 10-year follow-up study. *Ir. J. Psychol. Med.* 2007, 24, 117–126. [CrossRef] [PubMed]

54. Garland, M.R.; Hallahan, B.; McNamara, M.; Carney, P.; Grimes, H.; Hibble, J.R.; Harkin, A.; Conroy, R.M. Lipids and essential fatty acids in patients presenting with self-harm. *Br. J. Psychiatry* 2007, 190, 112–117. [CrossRef] [PubMed]

55. Bellino, S.; Bozzatello, P.; Rocca, G.; Bogetto, F. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid. *J. Psychopharmacol.* 2014, 28, 125–132. [CrossRef]

56. Bozzatello, P.; Rocca, P.; Bellino, S. Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: A follow-up study. *Clin. Drug Investig.* 2018, 38, 367–372. [CrossRef]

57. Stoffers, J.; Völlm, B.A.; Rücker, G.; Timmer, A.; Huband, N.; Lieb, K. Pharmacological interventions for borderline personality disorder. *Cochrane Database Syst. Rev.* 2010, 16, CD005653. [CrossRef]

58. Lieb, K.; Völlm, B.; Rücker, G.; Timmer, A.; Stoers, J.M. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. *Br. J. Psychiatry.* 2010, 196, 4–12. [CrossRef]

59. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed.; American Psychiatric Association: Arlington, VA, USA, 2013.

60. Choy, O.; Raine, A. Omega-3 Supplementation as a Dietary Intervention to Reduce Aggressive and Antisocial Behavior. *Curr. Psychiatry Rep.* 2018, 20, 32. [CrossRef]

61. Toro, R.; Garcia, J.; Basurto, F.Z. Antisocial Disorders in Adolescence and Youth, According to Structural, Emotional, and Cognitive Transdiagnostic Variables: A Systematic Review. *Int. J. Environ. Res. Public Health* 2020, 17, 3036. [CrossRef]
63. Verona, E.; Sprague, J.; Sadeh, N. Inhibitory control and negative emotional processing in psycho-pathy and antisocial personality disorder. J. Abnorm. Psychol. 2012, 121, 498–510. [CrossRef] [PubMed]

64. Cunha-Bang, S.; Vadskjaer, Hjortd, L.; Perfalk, E.; Beliveau, V.; Bock, C.; Szabolcs, L.; Thomsen, C.; Sestoft, D.; Svarer, C.; Knudsen, G.M. Serotonin 1B Receptor Binding Is Associated with Trait Anger and Level of Psychopathy in Violent Offenders. Biol. Psychiatry 2017, 82, 267–274. [CrossRef] [PubMed]

65. Virkkunen, M.E.; Horrobin, D.F.; Jenkins, D.K.; Manku, M. Plasma phospholipid essential fatty acids and prostaglandins in alcoholic, habitually violent, and impulsive offenders. Biol. Psychiatry 1987, 22, 1087–1096. [CrossRef]

66. Hibbeln, J.R.; Ferguson, T.A.; Blasbalg, T.L. Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation: Opportunities for intervention. Int. Rev. Psychiatry 2006, 18, 107–118. [CrossRef] [PubMed]

67. Tammm, J.D.; Steinsaltz, D.; Bester, D.; Semb-Andenæs, T.; Stein, J.F. A randomised double-blind placebo-controlled trial investigating the behavioural effects of vitamin, mineral and n-3 fatty acid supplementation in typically developing adolescent schoolchildren. Br. J. Nutr. 2016, 115, 361–373. [CrossRef]

68. Raine, A.; Portnoy, J.; Liu, J.H.; Mahoomed, T.; Hibbeln, J.R. Reduction in behavior problems with omega-3 supplementation in children aged 8–16 years: A randomized, double-blind, placebo-controlled, stratified, parallel-group trial. J. Child. Psychol. Psychiatry 2015, 56, 509–520. [CrossRef]

69. Raine, A.; Chu Fung, A.L.; Gao, Y.; Lee, T.M.C. Omega-3 supplementation, child antisocial behavior, and psychopathic personality: A randomized, double-blind, placebo-controlled, stratified, parallel-group trial. Eur. Child. Adolesc. Psychiatry 2020. [CrossRef]

70. Rodriguez-Hernandez, P.; Canals-Baeza, A.; Santamaria-Orleans, A.; Cachadiña-Domenech, F. Impact of Omega-3 Fatty Acids Among Other Nonpharmacological Interventions on Behavior and Quality of Life in Children with Compromised Conduct in Spain. J. Diet. Suppl. 2018, 17, 1–12. [CrossRef]

71. Gesh, C.B.; Hammond, S.M.; Hampson, S.E.; Eves, A.; Crowder, M.J. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Br. J. Psychiatry 2002, 181, 22–28. [CrossRef]

72. Raine, A.; Cheney, R.A.; Ho, R.; Portnoy, J.; Liu, J.; Snyder, L.; Joseph Hibbeln, J.; Richmond, T.S. Nutritional supplementation to reduce child aggression: A randomized, stratified, single-blind, factorial trial. J. Child. Psychol. Psychiatry 2016, 57, 1038–1046. [CrossRef] [PubMed]

73. Raine, A.; Ang, R.P.; Choy, O.; Hibbeln, J.R.; Ho, R.M.-H.; Lim, C.G.; Lim-Ashworth, N.S.J.; Ling, S.; Liu, J.C.T.; Ooi, Y.P.; et al. An omega-3 and social skills intervention for childhood externalizing behavior problems: A randomized, placebo-controlled, factorial trial. Psychol. Med. 2017. [CrossRef]

74. Uhl, G.R.; Koob, G.F.; Cable, J. The neurobiology of addiction. Nat. Neurosci. 2015, 18, 74–79. [CrossRef]

75. Yau, Y.H.C.; Potenza, M.N. Gambling Disorder and Other Behavioral Addictions: Recognition and Treatment. J. Affect. Disord. 2018, 234, 358–364. [CrossRef] [PubMed]

76. Lawrence, A.; Luty, J.; Bogdan, N.; Sahakian, B.; Clark, L. Problem gamblers share deficits in impulsive decision-making with alcoholic, habitually violent, and impulsive offenders. Biol. Psychiatry 1987, 22, 1087–1096. [CrossRef]

77. Buydens-Branchey, L.; Branchey, M.; Hibbeln, J.R. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 568–575. [CrossRef] [PubMed]

78. Song, C. Essential fatty acids as potential anti-inflammatory agents in the treatment of affective disorders. Mod. Trends Pharmacopsychiatr. 2013, 28, 75–89. [CrossRef]

79. Buydens-Branchey, L.; Branchey, M.; Hibbeln, J.R. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 568–575. [CrossRef] [PubMed]

80. Beier, A.M.; Lauritzen, L.; Galfalvy, H.C.; Cooper, T.B.; Oquendo, M.A.; Grunebaum, M.F.; Mann, J.J.; Sublette, M.A. Low plasma eicosapentaenoic acid levels are associated with elevated trait aggression and impulsivity in major depressive disorder with a history of comorbid substance use disorder. J. Psychiatr. Res. 2014, 57, e140. [CrossRef]

81. Egger, H.L.; Angold, A. Common emotional and behavioural disorders in preschool children: Presentation, nosology, and epidemiology. J. Child. Psychol. Psychiatry 2006, 47, 313–337. [CrossRef] [PubMed]

82. Mauri, M.; Nobile, M.; Bellina, M.; Crippa, A.; Brambilla, P. Light up ADHD: I. Cortical hemodynamic responses measured by functional Near Infrared Spectroscopy (fNIRS): Special Section on “Translational and Neuroscience Studies in Affective Disorders” Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summarise relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J. Affect. Disord. 2018, 234, 358–364. [CrossRef] [PubMed]

83. Puiu, A.A.; Wudarczyk, O.; Goerlich, K.S.; Votinov, M.; Herpertz-Dahlmann, B.; Turetsky, B.; Konrad, K. Impulsive aggression and response inhibition in attention-deficit/hyperactivity disorder and disruptive behavioral disorders: Findings from a systematic review. Neurosci. Biobehav. Rev. 2018, 90, 231–246. [CrossRef] [PubMed]

84. Blader, J.C.; Pliszka, S.R.; Jensen, P.S.; Schooler, N.R.; Kafantaris, V. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Pediatrics 2010, 126, e796–e806. [CrossRef]
86. Stevens, L.J.; Zentall, S.S.; Abate, M.L.; Kuczek, T.; Burgess, J.R. Omega-3 fatty acids in boys with behavior, learning, and health problems. *Physiol. Behav.* 1996, 59, 915–920. [CrossRef]

87. Gow, R.V.; Valleé-Tourangeau, F.; Crawford, M.A.; Taylor, E.; Ghebremeskel, K.; Bueno, A.A.; Hibbeln, J.R.; Sumich, A.; Rubia, K. Omega-3 fatty acids are inversely related to callous and unemotional traits in adolescent boys with attention deficit hyperactivity disorder. *Prostaglandins Leukot. Essent. Fatty Acids*. 2013, 88, 411–418. [CrossRef] [PubMed]

88. Colquhoun, I.; Bunday, S. A lack of essential fatty acids as a possible cause of hyperactivity in children. *Med. Hypotheses* 1981, 7, 673–679. [CrossRef]

89. Kohlböeck, G.; Glaser, C.; Tiesler, C.; Demmelmair, H.; Standl, M.; Romanos, M.; Koletzko, B.; Lehmann, I.; Heinrich, J.; LISAplus Study Group. Effect of fatty acid status in cord blood serum on children’s behavioral difficulties at 10 y of age: Results from the LISAplus study. *Am. J. Clin. Nutr.* 2011, 94, 1592–1599. [CrossRef]

90. Voigt, R.G.; Llorente, A.M.; Jensen, C.L.; Fraley, J.; Berretta, M.; Heird, W. A randomized, double-blind, placebo controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. *J. Pediatr.* 2001, 139, 189–196. [CrossRef]

91. Widhenhorn-Müller, K.; Schwanda, S.; Scholz, E.; Spitzer, M.; Bode, H. Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): A randomized placebo-controlled intervention trial. *Prostaglandins Leukot. Essent. Fat. Acids* 2014, 91, 49–60. [CrossRef]

92. Gustafsson, P.A.; Birberg-Thornberg, U.; Ducheń, K.; Landgren, M.; Malmberg, K.; Pelling, H.; Strandvik, B.; Karlsson, T. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. *Acta Paediatr.* 2010, 99, 1540–1549. [CrossRef] [PubMed]

93. Manor, I.; Magen, A.; Keidar, D.; Rosen, S.; Tasker, H.; Cohen, T.; Richter, Y.; Zaaroor-Regev, D.; Manor, Y.; Weizman, A. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open-label extension. *Eur. Psychiatry* 2012, 27, 335–342. [CrossRef] [PubMed]

94. Stevens, L.; Zhang, W.; Peck, L.; Kuczek, T.; Grevstad, N.; Mahon, A.; Zentall, S.S.; Eugene Arnold, L.; Burgess, J.R. EPA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. *Lipids* 2003, 38, 1007–1021. [CrossRef] [PubMed]

95. Hirayama, S.; Hamazaki, T.; Terasawa, K. Eept of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder—A placebo-controlled double-blind study. *Eur. J. Clin. Nutr.* 2004, 58, 467–473. [CrossRef] [PubMed]

96. Anand, P.; Sachdeva, A. Effect of Poly Unsaturated Fatty Acids Administration on Children with Attention Deficit Hyperactivity Disorder: A Randomized Controlled Trial. *J. Clin. Diagn. Res.* 2016, 10, OC01–OC05. [CrossRef] [PubMed]

97. Bos, D.J.; Oranje, B.; Veerhoek, E.S.; van Diepen, R.; Weusten, J.; Demmelmair, H.; Koletzko, B.; De Sain-Van Der Velden, M.G.; Eiland, A.; Hoekema, M.; et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. *Neuropsychopharmacology* 2015, 40, 2298–2306. [CrossRef]

98. Chang, J.P.; Su, K.P.; Mondelli, V.; Satyanarayanan, S.K.; Yang, H.T.; Chiang, Y.J.; Chen, H.T.; Pariante, C.M. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. *Transl. Psychiatry* 2019, 20, 303. [CrossRef]

99. Bélanger, S.A.; Vanasse, M.; Sphais, S.; Sylvester, M.P.; Lippé, S.; L’Heureux, F.; Ghadirian, P.; Vanasse, C.M.; Levy, E. Omega-3 fatty acid treatment of children with attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study. *Paediatr. Child. Health* 2009, 14, 89–98. [CrossRef]

100. Johnson, M.; Östlund, S.; Fransson, G.; Kadesjo, B.; Gillberg, C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: A randomized placebo-controlled trial in children and adolescents. *J. Atten. Disord.* 2009, 12, 394–401. [CrossRef]

101. Matsudaira, T.; Gow, R.V.; Kelly, J.; Murphy, C.; Potts, L.; Sumich, A.; Ghebremeskel, K.; Crawford, M.A.; Taylor, E. Biochemical and Psychological Effects of Omega-3/6 Supplements in Male Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Clinical Trial. *J. Child. Adolesc. Psychopharmacol.* 2015, 25, 775–782. [CrossRef]

102. Assareh, M.; Davari Ashitian, R.; Khademi, M.; Jazayeri, S.; Rai, A.; Nikoo, M. Efficacy of Polysaturated Fatty Acids (PUFA) in the Treatment of Attention Deficit Hyperactivity Disorder. *J. Atten. Disord.* 2017, 21, 78–85. [CrossRef] [PubMed]

103. Richardson, A.; Puri, B. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2002, 26, 233–239. [CrossRef]

104. Sinn, N.; Bryan, J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. *J. Dev. Behav. Pediatr.* 2007, 28, 82–91. [CrossRef] [PubMed]

105. Perera, H.; Jeewandara, K.C.; Seneviratne, S.; Guruge, C. Combined ω-3 and ω-6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment. *J. Child. Neurol.* 2012, 27, 747–753. [CrossRef]

106. Barragán, E.; Breuer, D.; Döpflner, M. Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children with ADHD. *J. Atten. Disord.* 2017, 21, 433–441. [CrossRef]

107. Garland, M.R.; Hallahan, B. Essential fatty acids and their role in conditions characterised by impulsivity. *Int. Rev. Psychiatry* 2006, 18, 99–105. [CrossRef]
108. Bozzatello, P.; Brignolo, E.; De Grandi, E.; Bellino, S. Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. J. Clin. Med. 2016, 27, 67. [CrossRef]

109. Hamazaki, T.; Hamazaki, K. Fish oils and aggression or hostility. Prog. Lipid Res. 2008, 47, 221–232. [CrossRef]

110. Appleton, K.M.; Rogers, P.J.; Ness, A.R. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr. Res. Rev. 2008, 21, 13–41. [CrossRef]

111. Freeman, M.P.; Fava, M.; Lake, J.; Trivedi, M.H.; Wisner, K.L.; Mischoulon, D. Complementary and alternative medicine in major depressive disorder: The American Psychiatric Association Task Force report. J. Clin. Psychiatry 2010, 71, 669–681. [CrossRef]

112. European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 2012, 10, 2815.

113. Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H.; et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090–1098. [CrossRef]

114. Tanaka, K.; Ishikawa, Y.; Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Saito, Y.; Matsuzawa, Y.; Sasaki, J.; Oikawa, S.; Hishida, H.; et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: Subanalysis of the JELIS trial. Stroke 2008, 39, 2052–2058. [CrossRef] [PubMed]

115. Song, C.; Li, X.; Leonard, B.E.; Horrobin, D.F. Effects of dietary n-3 or n-6 fatty acids on interleukin-1β-induced anxiety, stress, and inflammatory responses in rats. J. Lipid Res. 2003, 44, 1984–1991. [CrossRef] [PubMed]

116. Hartweg, J.; Perera, R.; Montori, V.; Dinneen, S.; Neil, H.A.; Farmer, A. Omega-3-polyunsaturated fatty acids (HUFAs) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2008. [CrossRef] [PubMed]

117. Hartweg, J.; Farmer, A.J.; Holman, R.R.; Neil, A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr. Opin. Lipidol. 2009, 20, 30–38. [CrossRef] [PubMed]

118. MacLean, C.H.; Mojica, W.A.; Morton, S.C.; Pencharz, J.; Hasenfeld, G.R. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid. Rep. Technol. Assess. (Summ.) 2004, 89, 1–4.

119. Bloomer, R.J.; Larson, D.E.; Fisher-Wellman, K.H.; Galpin, A.J.; Schilling, B.K. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: A randomized, placebo controlled, cross-over study. Lipids Health Dis. 2009, 8, 36. [CrossRef] [PubMed]

120. VKM (Norwegian Scientific Committee for Food Safety). Opinion of the Steering Committee of the Norwegian Scientific Committee for Food Safety: Evaluation of Negative and Positive Health Effects of n-3 Fatty Acids as Constituents of Food Supplements and Fortified Foods. Available online: http://english.vkm.no/dav/031c000d1a.pdf (accessed on 20 June 2016).

121. Farmer, A.; Montori, V.; Dinneen, S.; Clar, C. Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2001. [CrossRef]